RIDE FOR LMS
2016 Pelotonia information: http://pelotonia.org
In an effort to raise LMS awareness, the National LeioMyoSarcoma Foundation sponsored a bike rider in the 2015 Pelotonia. More than 6,700 riders from 40 states and eight countries joined more than 2,300 volunteers supporting their efforts from August 7 through 9. Based on its rider base, Pelotonia is now the largest single-event biking fundraiser in the U.S.
Our rider, Mark Lackey, cycled the challenging 100-mile route in honor of everyone who has been affected by LMS. Show your support and ride along with us by becoming a virtual rider and make a donation to help raise funds for LMS awareness and cancer research.
This is a great way to pay tribute to survivors, caregivers, and loved ones who have lost their battles with LMS or to celebrate milestones like birthdays, anniversaries, dances with No Evidence of Disease (NED), or just simply to celebrate life.
NLMSF encourages all avid or dedicated bike riders to ride in the Pelotonia Ride to represent NLMSF. The location will be Columbus, Ohio, and we’d like to see many Ohioans.
Rider Profile: Mark Lackey
Mark Lackey was honored to be riding for the second year in the Pelotonia Bike Fundraiser on behalf of everyone who has been affected by LMS – survivors, caregivers, and loved ones that have lost their battle with LMS. This ride had special meaning for Mark because he rode for his next-door neighbor, Annemarie, a five-year survivor who has inspired Mark in her battle to defeat cancer. 100% of the money each rider raises goes directly to Cancer Research at the Ohio State University Comprehensive Cancer Center, Arthur James Cancer Hospital, and Richard J. Solove Research Institute.
Donations in support of Mark,who has ridden more than 100 miles each year, are still being accepted by going through PayPal at www.nlmsf.org website until Oct. 9th.
Along with our readers, who see this as an opportunity to help with Cancer Research, there must be some OSU students and alumni who want to throw in their support for such a worthwhile cause.
Mark Lackey was born and raised in Columbus, Ohio, and is the President of Happy Chicken Farms and Merry Milk Maid food distributors, local family-owned and -operated companies. He lives with his wife and three children in Hilliard. Mark is currently training for his fourth Ironman Triathalon, an endeavor started when he turned 40. His first long-distance ride was dedicated to his youngest daughter, Andrea, who struggles with Type 1 diabetes. Cancer has touched many loved ones in Mark’s family, including his grandfather, grandmother, father, sister-in-law, and niece. Mark is honored to be riding in this years’s Peletonia on behalf of everyone who has been affected by LMS – survivors, caregivers, and loved ones that have lost their battle with LMS. This ride also has special meaning to Mark because he will be riding for his next-door-neighbor of 11 years, Annemarie. Riding on her behalf puts extra meaning behind the long, grueling 5-6 hours rides endured while training for an Ironman. Annemarie is a 4-year LMS survivor and has inspired Mark in her battle to defeat cancer. Mark plans to do the full 100 miles of Pelotonia, as for him, its“go all or go home!”
PELOTONIA BIKE RIDE FUNDRAISER
<< New text box >>
In its 7th year, more than 6,700 cyclists expected to ride in hopes of One Goal: End Cancer
Pelotonia, the grassroots fundraiser with One Goal: End Cancer, projects fundraising to surpass $18 million this year, bringing total amount raised since the first ride in 2009 to more than $60 million. This year, more than 6,700 riders and counting, from 40 states and eight countries, will join more than 2,300 volunteers supporting their efforts from August 7 through 9. Based on its rider base, Pelotonia is now the largest single-event biking fundraiser in the U.S., surpassing the Needham, Massachusetts-based Pan-Massachusetts Challenge, which, in its 33rd year had 5,450 riders.
The weekend-long ride and celebration will begin in downtown Columbus at Columbus Commons, 160 S. High Street. In its first four years, Pelotonia has raised a total of more than $42 million for a broad range of cancer research initiatives. In 2012, it surpassed the Needham, Massachusetts-based Pan-Massachusetts Challenge as the largest single-event biking fundraiser in the U.S., based on the number of riders.
Riders will cover as many as 180 miles during two days, starting in Columbus before finishing at one of five locations. Riders choose between a one day 25-mile ride, 50-mile ride, 75-mile ride, 100-mile ride, or two day 150-mile and 180-mile rides. The first day ride ends at Kenyon College in Gambier, Ohio, and the second day ride concludes at Market Square in New Albany, Ohio . Each rider makes a commitment to raise a minimum of $1,200 to $2,200 for cancer research based on his or her route choice. In each of its first three rides, Pelotonia riders, on average, have exceeded stipulated fundraising minimums by approximately 30 percent.
Pelotonia donates 100 percent of every rider-raised dollar directly to The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. Pelotonia is able to maintain that rate because of the financial support of generous Pelotonia funding partners. Primary financial partners include Huntington Bank, Limited Brands Foundation and Richard and Peggy Santulli. Other leading financial partners include American Electric Power Foundation, Nationwide Insurance, Cardinal Health Foundation, The Schott Family Foundation and The Scotts Miracle-Gro Company.
Funds raised by Pelotonia are allocated to four primary research areas from within The Ohio State University Comprehensive Cancer Center. Programs include a fellowship program, funding student researchers; Idea Grants, funding teams of researchers; recruitment of some of the world’s best cancer researchers and programs, as well as retention of current researchers and programs.
Along the 180-mile route, more than 2,300 volunteers will support riders by providing snacks, beverages, first aid assistance and bike maintenance services, with thousands of supporters cheering riders throughout their ride.
About the James Cancer Hospital and Solove Research Institute
Leveraging the University’s academic depth and breadth, The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is speeding the discovery and delivery of molecular- and genetic-based prevention and treatment for individual cancers, leading to improved outcomes, faster responses, more options and fewer side effects. More than 300 researchers from 12 of Ohio State’s 14 colleges collaborate on breakthrough discoveries for new, more targeted ways to prevent, detect, treat, and cure individual cancers. The James has more than 200 oncologists, each of whom specialize in just one type of cancer.
In 2014, Ohio State opened the new James, a 21st century cancer hospital, with 21 floors and 306 beds. A founding member of the National Comprehensive Cancer Network and one of the only 41 NCI-designated comprehensive cancer centers in the nation, Ohio State is rated exceptional-the highest rating given by the National Cancer Institute, and is ranked among the top 20 cancer hospitals in the nation by US News and World Report.
At OSUCCC – James, we’re committed to creating a cancer-free world. In December 2014, we are opening the doors of the new James Cancer Hospital and Solove Research Institute, a transformational facility that fosters collaboration and integration of research and clinical cancer care. This 21-level hospital will help revolutionize the way cancer prevention and care are provided in this nation, with world-class oncologists and cancer researchers working side-by-side to unlock the mysteries of why we get cancer and, using those discoveries, move from treating cancer to preventing it from ever occurring.
The patients served by the new hospital will find themselves at the intersection of research, education and customized care. Research and education spaces will be located on every floor, enhancing our bench-to-beside approach to patient care and giving patients early access to new treatments and tools.